You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The insurer is the latest to provide coverage for NanoString's gene expression-based breast cancer recurrence risk test.
Natera said that a greater proportion of NIPTs for average-risk pregnancies are being reimbursed, while reimbursement for microdeletion testing is declining.
Bank of America, Phoenix Children's Hospital, and Sanford Health said they would cover NantHealth's GPS Cancer test for some cancers.
Aetna considers the test "medically necessary" and the decision opens the door for 19 million people to access the risk classifier test.
Sequenom has secured in-network status with seven state Anthem BCBS plans to provide NIPT to both high- and average-risk pregnancies.
The decision was made after Geisinger researchers and clinicians presented the health plan with evidence of the clinical utility of exome sequencing.
The in-network contracts provide coverage for insured patients in Connecticut, Maine, and New Hampshire for both high- and average-risk pregnancies.
Exact Sciences' CEO recently discussed the added coverage on a call with analysts to discuss Exact's Q4 earnings.
The company said the agreement will make its cancer diagnostics and genomic tests available to more than 2.6 million people.
NantHealth is also planning to launch a 20,000-patient multi-arm, multi-drug trial based on profiling patients' tumors with its GPS Cancer test.
Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.
NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.
Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.
In Science this week: review discusses advances in liquid biopsies, and more.